AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Description: AcelRx Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct's pharmaceuticals report, “AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- AcelRx Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AcelRx Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AcelRx Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AcelRx Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AcelRx Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AcelRx Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AcelRx Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AcelRx Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AcelRx Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Contents:

List of Tables
List of Figures
AcelRx Pharmaceuticals, Inc. Snapshot
AcelRx Pharmaceuticals, Inc. Overview
Key Information
Key Facts
AcelRx Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
AcelRx Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
AcelRx Pharmaceuticals, Inc. – Pipeline Products Glance
AcelRx Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
AcelRx Pharmaceuticals, Inc. – Drug Profiles
ARX-01
Product Description
Mechanism of Action
R&D Progress
ARX-02
Product Description
Mechanism of Action
R&D Progress
ARX-03
Product Description
Mechanism of Action
R&D Progress
AcelRx Pharmaceuticals, Inc. – Pipeline Analysis
AcelRx Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
AcelRx Pharmaceuticals, Inc. Pipeline Products by Route of Administration
AcelRx Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
AcelRx Pharmaceuticals, Inc. – Recent Pipeline Updates
AcelRx Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 01, 2010: AcelRx Completes End-Of-Phase II Meeting With FDA For ARX-02 For Treatment Of Cancer Pain
May 25, 2010: AcelRx Announces Positive Phase II Results Of ARX-02 Sufentanil NanoTab For Treatment Of Cancer Breakthrough Pain
Oct 30, 2009: AcelRx Announces Successful Completion Of End-of-Phase II Meeting On ARX-01 For Post-Operative Pain Management
Oct 22, 2009: AcelRx Announces Positive Results From Phase II Study Of ARX-03 For Procedural Sedation, Anxiolysis & Analgesia
Jul 22, 2009: AcelRx Announces Perfect Performance Of Handheld Component Of ARX-01 Sufentanil NanoTab PCA System In Phase II Study
Jun 29, 2009: AcelRx Announces Positive Phase II Results Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
Apr 22, 2009: AcelRx Announces Initiation Of Phase II Trial For ARX-02 In Breakthrough Cancer Pain
Jan 12, 2009: AcelRx Pharmaceuticals Reports Positive Results From Phase I Clinical Trial Of ARX-03 In Treating Procedural Pain And Anxiety
Financial Deals Landscape
AcelRx Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
AcelRx Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
AcelRx Pharmaceuticals Secures $12 Million In Financing
AcelRx Pharmaceuticals Secures $20.21 Million In Venture Financing
AcelRx Pharmaceuticals Secures $19.79 Million In Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Ordering: Order Online - http://www.researchandmarkets.com/reports/1446972/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Web Address: http://www.researchandmarkets.com/reports/1446972/
Office Code: SCD2VXT5

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World